CEC Oncology
@CEC_Onc
Followers
373
Following
991
Media
406
Statuses
1K
Live & enduring accredited hem/onc activities for physicians (ACCME), nurses (ANCC), and pharmacists (ACPE): https://t.co/9vVpfCGQ56…
Radnor, PA
Joined March 2017
Thanks for joining The MEKtrix: Advancing #Neurofibromatosis Type 1 Care! Apply these key takeaways in your practice: 🏥 Refer patients to NF1 centers 🤝 Build multidisciplinary teams 🧭 Plan early for transition to adult care Watch the archive: https://t.co/YTM6WFvSIO
#MedEd
0
0
0
🧬 1 week to go! Join us Nov 21 for a deep dive into #NF1 management & evolving roles of #MEKinhibitors in PN. Essential insights for #neurooncology teams. Register now: https://t.co/87MO1YBHWq
#NF1Care #PN #MedEd #CME #Neurofibromatosis #CEConcepts
0
0
0
Clinicians: Are you using the right ADC for the right patient? This 30-min CE will guide you through mechanisms, payloads, and real-world implications. 🎓 https://t.co/UzCwyt25tW
#CME #ADCinMBC #OncPharm
ceconcepts.com
Antibody-drug conjugates (ADCs) have recently been approved to treat HER2-negative metastatic breast cancer (MBC). In an ADC, a cytotoxic chemotherapeutic agent is conjugated to a monoclonal antibody...
0
0
0
🚑 Patient on CAR T presents with altered mental status... What’s your next move? 🎓 This CME equips you to manage neurotoxicity, CRS & more. 📲 https://t.co/5H6KLHH6cd
#ICANS #CRS #CancerImmunotherapy #EMCare
ceconcepts.com
As the use of immunotherapies for the treatment of cancer expands, emergency medicine (EM) clinicians will need a further understanding of their mechanisms of action (MOAs) to better guide diagnosis...
0
0
0
🧠 Learn to recognize the signs of NF1 early, treat PN effectively, and build care plans that evolve over time. 🎓 1 free CME credit → https://t.co/ULWSXc3xBa
#NF1Awareness #Oncology #PediatricCME #MultidisciplinaryCare
ceconcepts.com
Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of near- and long-term clinical manifestations makes diagnosis and management of the...
0
0
0
🚨 Platinum-resistant ovarian cancer is tough to treat, but novel FRα ADC therapies are changing the game. Learn how these advancements are reshaping patient outcomes. 🔗 Participate now: https://t.co/dLUBFmVXLg
#CancerCare #ClinicalEducation #OncologyUpdates
ceconcepts.com
Ovarian cancer typically responds well to initial platinum-based chemotherapy treatment. However, most tumors subsequently relapse and eventually become resistant, for which the prognosis is poor and...
0
1
2
Short on time? This 30-min CE BriefCase delivers clinical trial takeaways on ADCs in HER2-negative MBC—no fluff, all action. 💻 Watch now: https://t.co/FpCjBGFHOC
#MBC #OncologyNPs #PharmacistsInOncology
ceconcepts.com
The rapidly shifting therapeutic landscape for HER2-negative metastatic breast cancer (MBC) challenges clinicians to stay up-to-date on emerging clinical trial data, as well as recommendations on...
0
0
0
🧠 NF1 is complex. This CME explores how to: ✔ Spot clinical signs early ✔ Use MEK inhibitors effectively ✔ Build interprofessional care plans ⏯ Available now: https://t.co/fIuH1b1rZZ
#NF1 #Neurofibromatosis #CME
ceconcepts.com
Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including...
0
0
0
Complex cases need coordinated care. This livestream will guide you in creating interprofessional NF1 plans, including MEK inhibitor management. 📅 Nov 21 | 10:15 PM EST 🔗 https://t.co/qk8jfCW33W
#NF1 #RareCancer #ContinuingEducation
ceconcepts.com
Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complic...
0
0
0
The future of upper GI cancer care is biomarker-driven. Learn how to optimize treatment decisions with the latest evidence & multidisciplinary insights. 🎥 Watch + earn CME: https://t.co/f1KO3ksC6z
@KlempnerSam @Sam_Cytryn
#CancerCME #GIoncology #BiomarkerTesting
ceconcepts.com
Upper gastrointestinal (GI) cancers are often undetected until late stages, leading to a poor prognosis. Treatment may be delayed or inappropriately assigned due to a lack of robust biomarker...
0
0
0
When managing HER2-negative MBC, what’s your plan for AE mitigation? Build it around this new 30-min BriefCase featuring clinical and patient insights. 🎯 Watch now: https://t.co/q1KqW7WGMe
#QoLInCare #OncologyNursing #MBCsupport
ceconcepts.com
Patients with HER2-negative metastatic breast cancer (MBC) who receive antibody-drug conjugates (ADCs) may experience a spectrum of adverse events (AEs) that can lower their quality of life (QoL)....
0
0
0
That’s a wrap on #ALLFSP 2025! 👏 A huge thank you to our incredible fellows, faculty, and patient presenters for a powerful weekend of education and collaboration. Until next year! 🔗 https://t.co/7y1gY9ykUu
#ALLFSP #HemeOnc #MedicalEducation #LeukemiaResearch
info.ceconcepts.com
Information about the 3rd Annual Acute Lymphoblastic Leukemia Fellows Scholar Program
0
0
0
The learning begins! 🩸 Kicking off #ALLFSP 2025 with introductions and our first round of educational sessions led by expert faculty. Can’t wait to see what insights come from today’s discussions. 🔗 https://t.co/7y1gY9ykUu
#ALLFSP #HemeOnc #FellowEducation
info.ceconcepts.com
Information about the 3rd Annual Acute Lymphoblastic Leukemia Fellows Scholar Program
0
0
0
“Patient voices bring the science to life.” We’re honored to have Stephanie Samolovitch, MSW, sharing her patient perspective at #ALLFSP 2025 — reminding fellows why their work matters most. #LeukemiaCare #PatientPerspective
0
0
0
Welcome to #ALLFSP 2025! Fellows are checking in and preparing for a weekend of collaboration, education, and expert insights in acute lymphoblastic leukemia. From interactive sessions to small group case discussions, this program builds the next generation of leukemia leaders.
0
0
0
Registration is open at #ALLFSP 2025! 🙌 Fellows are arriving and gearing up for two days of interactive learning and case-based discussions in acute lymphoblastic leukemia. Stay tuned for highlights! 🔗 https://t.co/7y1gY9ykUu
#ALLFSP #HemeOnc #MedicalEducation
info.ceconcepts.com
Information about the 3rd Annual Acute Lymphoblastic Leukemia Fellows Scholar Program
0
1
0
Understand ADCs beyond the basics. Learn how to align treatment with patient needs in HER2-negative MBC. 🎓 Free 30-min CE: https://t.co/UzCwyt25tW
#OncologyCME #BreastCancerCare #CEforNurses
ceconcepts.com
Antibody-drug conjugates (ADCs) have recently been approved to treat HER2-negative metastatic breast cancer (MBC). In an ADC, a cytotoxic chemotherapeutic agent is conjugated to a monoclonal antibody...
0
0
0
The 3rd Annual Acute Lymphoblastic Leukemia Fellows Scholar Program kicks off tomorrow in Orlando! 🌴 Can’t wait to see the next generation of #OncFellows dive into real-world #ALLeducation with our expert faculty: @AyaOncologist, @LuskinMarlise, Luke Maese, DO, and Julie
info.ceconcepts.com
Information about the 3rd Annual Acute Lymphoblastic Leukemia Fellows Scholar Program
0
0
0
November is Lung Cancer Awareness Month—a time to amplify conversations about prevention, early detection, and the latest treatment advancements. 🫁 Let’s work together to spread awareness and support innovations in lung cancer care. Every effort counts in saving lives and
0
0
0